Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.56 |
| ▸ | F12 | P00748 | 1/20 | 0.56 |
| ▸ | NCF1 | P14598 | 1/20 | 0.56 |
| ▸ | NOS3 | P29474 | 1/20 | 0.56 |
| ▸ | NOS1 | P29475 | 1/20 | 0.56 |
| ▸ | NOS2 | P35228 | 1/20 | 0.56 |
| ▸ | BACE1 | P56817 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29923403 | 0.75 | PLAU (0.60) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL199273 | 0.75 | PLAU (0.60) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL276689 | 0.74 | CLK1 (0.44) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL4797349 | 0.73 | PLAU (0.58) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL30522769 | 0.73 | PLAU (0.58) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL24663121 | 0.73 | CYP2A6 (0.58) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL27740667 | 0.73 | PLAU (0.57) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL277424 | 0.73 | CYP3A4 (0.44) | ALDH1A1SMN1; SMN2LMNACYP3A4PMP22 | |
| SCHEMBL24061845 | 0.73 | PLAU (0.52) | PLAUCYP2A6F12NCF1NOS3 | |
| SCHEMBL1567649 | 0.71 | PLAU (0.56) | PLAUCYP2A6F12NCF1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1924 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240210412-A1 | SULFONYL-TRIAZOLE COMPOUNDS USEFUL AS LIGANDS AND INHIBITORS OF PROSTAGLANDIN REDUCTASE 2 | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-06-27 | — | — | US | claimed |
| US-20240199701-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-06-20 | — | — | US | claimed |
| CN-118159549-A | Immunomodulators | 百时美施贵宝公司 | 2024-06-07 | — | — | CN | claimed |
| EP-4314012-A1 | IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2024-02-07 | — | — | EP | claimed |
| CN-117157306-A | Immunomodulators | 百时美施贵宝公司 | 2023-12-01 | — | — | CN | claimed |
| WO-2023178324-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING SALTS OF SALCAPROZATE AND NICOTINAMIDE FOR IMPROVING ORAL BIOAVAILABILITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-09-21 | — | — | WO | claimed |
| WO-2023165591-A1 | COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS | IMMUTHER PHARMATECH (SHANGHAI) CO., LTD. (CN) | 2023-09-07 | — | — | WO | claimed |
| US-11697812-B2 | Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2023-07-11 | — | — | US | claimed |
| WO-2023069994-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-27 | — | — | WO | claimed |
| US-11359198-B2 | Extended dicer substrate agents and methods for the specific inhibition of gene expression | DICERNA PHARMACEUTICALS, INC. (US) | 2022-06-14 | — | — | US | claimed |
| WO-2005033066-A2 | ARYLALKYLCARBAMATE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2005-04-14 | — | — | WO | claimed |
| WO-2004067498-A2 | ARYL ALKYL CARBAMATE DERIVATIVES PRODUCTION AND USE THEREOF IN THERAPY | SANOFI-AVENTIS (FR) | 2004-08-12 | — | — | WO | claimed |
| US-6576628-B1 | Matrix metalloprotease inhibitors; arthritis, corneal ulcers, arteriosclerosis | ROCHE DIAGNOSTICS GMBH (DE) | 2003-06-10 | — | — | US | claimed |
| US-5801181-A | Amino alcohol substituted cyclic compounds | CELL THERAPEUTICS, INC. (US) | 1998-09-01 | — | — | US | claimed |
| EP-0860435-A1 | Pyridazin-3-one derivatives and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-08-26 | — | — | EP | claimed |
| EP-0540673-B1 | ACETYLENE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LAB (US) | 1996-10-16 | — | — | EP | claimed |
| US-5439874-A | Preemergence, postemergence herbicides | BAYER AKTIENGESELLSCHAFT (DE) | 1995-08-08 | — | — | US | claimed |
| EP-0540673-A4 | — | — | 1994-04-27 | — | — | EP | claimed |
| EP-0540673-A1 | ACETYLENE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY. | ABBOTT LAB (US) | 1993-05-12 | — | — | EP | claimed |
| WO-1992001682-A1 | ACETYLENE DERIVATIVES HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LABORATORIES (US) | 1992-02-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199701-A1 | IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | PLAU 4002/4885CYP2A6 4871/4885F12 4520/4885 |
| US-20240210412-A1 | SULFONYL-TRIAZOLE COMPOUNDS USEFUL AS LIGANDS AND INHIBITORS OF PROSTAGLANDIN REDUCTASE 2 | PTGDR2, PTGFR, PTGDR | PLAU 2684/4885CYP2A6 656/4885F12 2861/4885 |
| US-11697812-B2 | Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA | TTR, RNASE1, SARNP | PLAU 2178/4885CYP2A6 4470/4885F12 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.